- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745706
Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation (DISCERN-AF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients scheduled to undergo a first time ablation for AF will be implanted with an implantable loop recorder (ILR), capable of automatically recording episodes of AF, 3 months prior to their ablation procedure. Patients will also be given a standardized diary in which they will record all perceived episodes of AF. Patients will have the data from the ILR downloaded prior to their ablation to record baseline AF data.
A blanking period of 3 months will be used to censor early recurrences post-ablation. A 'successful' AF ablation will be defined as a lack of AF episodes > 2min at least 3 months post-ablation. A 'Failure' AF ablation will encompass all patients not meeting the definition of 'success'. Redo ablation procedures will be allowed in this protocol for patients who continue to have AF recurrences beyond the first three months post-ablation.
After the patient's ablation procedure, patients will be followed every 3 months for 18 months. At each follow-up visit data on AF episodes from the ILR and the patient diaries will be collected. Patients will be blinded to the data downloaded from the device.
Further data will be collected as the patient study follow-up period has been extended to include a 30-month post-ablation visit with device interrogation as device battery is 36-42 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 4R2
- Victoria Cardiac Arrhythmia Trials Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- QEII Health Sciences Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences Centre
-
London, Ontario, Canada, N6A 4G5
- London Health Sciences Centre
-
Newmarket, Ontario, Canada, L3Y 2P9
- Southlake Regional Health Centre
-
Ottawa, Ontario, Canada, K1Y 4W7
- University of Ottawa Heart Institute
-
-
Quebec
-
Montréal, Quebec, Canada, H3G 1A4
- Hôpital Général de Montréal-McGill
-
Québec, Quebec, Canada, G1V 4G5
- Hôpital Laval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years old.
- First-time ablation procedure for AF.
- Symptomatic AF which has been refractory to at least one antiarrhythmic medication. "Symptomatic" patients should be patients who feel that they are aware of when they are in or out of AF. Symptoms may include palpitations, shortness of breath, chest pain, fatigue, or other symptoms, or any combination of the symptoms listed above.
- Patients must have paroxysmal or persistent AF. Paroxysmal patients should have had at least 4 episodes of AF in the 6 months prior to assessment/ablation. Paroxysmal AF is defined as AF which spontaneously terminates within 7 days. Persistent AF is defined as AF which sustains for longer than 7 days, or AF lasting less than 7 days which requires either pharmacologic or electrical cardioversion.
- At least one episode of AF must have been documented by ECG or Holter within 12 months of inclusion in the study.
- No contraindication to systemic anticoagulation with heparin or coumadin.
- Patients must be able and willing to provide written informed consent to participate in the study.
Exclusion Criteria:
- Patients with permanent atrial fibrillation. Permanent AF is defined as chronic, persisting AF (typically more than 1 year) for which cardioversion (pharmacologic or electrical) has failed or will never be attempted.
- Patients with AF felt to be secondary to an obvious reversible cause.
- Patients with contraindications to systemic anticoagulation with heparin or coumadin.
- Patients who have previously undergone atrial fibrillation ablation.
- Patients who are or may potentially be pregnant.
- Left atrial size > or equal to 55 mm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: A
Implantable Loop Recorder (ILR) implant
|
Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry.
Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of asymptomatic versus symptomatic AF pre-ablation
Time Frame: 3 months
|
3 months
|
Incidence of asymptomatic versus symptomatic AF recurrence > 3months post-AF ablation in patients with "success" after ablation.
Time Frame: 30 months
|
30 months
|
Incidence of asymptomatic versus symptomatic AF recurrence > 3 months post-AF ablation in patients with "failure" after ablation
Time Frame: 30 months
|
30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of peri-procedural and post-procedural embolic events
Time Frame: 24 hours
|
24 hours
|
Correlation of early recurrences (<3 months post-ablation) to late recurrences (> 3 months post-ablation)
Time Frame: 3-30 months
|
3-30 months
|
Incidence of very late AF recurrence (beyond 12 months psot-ablation) in "successful" patients post-ablation (determined both by AF episodes and burden)
Time Frame: 30 months
|
30 months
|
Comparison of "success" and "failure" rates as determined by ILR versus traditional, clinically-indicated ECG and holter monitoring
Time Frame: 30 months
|
30 months
|
Cost-effectiveness analysis of using ILR monitoring for post-AF ablation monitoring versus traditional follow-up (ECGs, holter, loop recorders)
Time Frame: 30 months
|
30 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Atul Verma, M.D., Southlake Regional Health Centre
- Principal Investigator: David Birnie, M.D., Ottawa Heart Institute Research Corporation
- Principal Investigator: Paul Novak, M.D., Royal Jubilee Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UOHI-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on Implantable Loop Recorder (ILR)
-
Dr. Adrian BaranchukMedtronicCompletedAtrial Fibrillation | Obstructive Sleep ApneaCanada
-
Odense University HospitalCompletedAtrial FibrillationDenmark, Sweden, Russian Federation
-
Hospital San Carlos, MadridFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIRecruitingPersistent Atrial FibrillationSpain
-
4th Military Clinical Hospital with Polyclinic,...Recruiting
-
Leonardo Calò, MDNot yet recruiting
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Salud Carlos III; Spanish Society of Cardiology; Sanidad de Castilla...Active, not recruitingMyocardial Infarction | Death, Sudden | Ventricular Tachycardia | Implantable Defibrillator User | Myocardial DysfunctionSpain
-
Canadian Institutes of Health Research (CIHR)Vanderbilt UniversityCompletedHeart Block | Syncope | Conduction Disorder of the HeartUnited Kingdom, Canada, United States, Malaysia, Japan
-
Barts & The London NHS TrustCompleted
-
University of PennsylvaniaMedtronicCompletedAtrial FibrillationUnited States
-
Medtronic ItaliaMedtronicWithdrawnArrhythmias, Cardiac | Bradycardia | SyncopeSaudi Arabia, Italy, Japan, United Kingdom, Germany, Iceland, India, South Africa, Sweden